Neurophos

Austin, TX · Founded 2020 · Privately Held (backing)

Manufacturer of an optical processor designed to bypass the resistive losses of pushing currents through circuits to gain efficiency. Neurophos is based in Austin, TX and was founded in 2020. It was valued at $310 million at its Series A in Jan 2026, the last priced event on record. It has raised $119 million across 5 recorded rounds; the latest was a $109 million Series A in Jan 2026.

PMV mark · valuation
$310.0M
Oct 2026
Priced at
its Series A
Jan 2026
Total raised
$119.2M
Last round
Later Stage VC (Series A)
Jan 2026

Capitalization table

6 share classes, by liquidation seniority
ClassLiq. prefIssue price
Seed-1▮▮
Seed-2▮▮
Seed-3▮▮
Series A-1▮▮
Series A-2▮▮
Series A-3▮▮
Preferences, participation and issue prices are Pro.Unlock preferences + participation

Membership and data by Private Market View

Free account
More of Neurophos with a free account
  • ·Post-money valuations for 4 rounds
  • ·The complete investor list: 29 names
  • ·Watch Neurophos: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Reading Neurophos's cap table

Share classes are listed senior-first: in a sale or liquidation, higher-seniority preferred stock is paid its liquidation preference before junior classes and common see proceeds. A participating class takes its preference and shares in the remainder; a non-participating class chooses one or the other.

The original issue price is what investors paid per share in that class’s round — read against current secondary prices, it shows which investors are above or below water.

Frequently asked about Neurophos

How many share classes does Neurophos have?
Neurophos has 6 recorded share classes, listed by liquidation seniority — Seed-1 is the most senior.
How many shares has Neurophos authorized?
Across its 6 recorded classes, Neurophos has authorized 35,439,677 shares.
Where does Neurophos's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Neurophos's 5 recorded funding rounds.